Development of a rational framework for the therapeutic efficacy of fecal microbiota transplantation for calf diarrhea treatment

Islam, Jahidul; Tanimizu, Masae; Shimizu, Yu; Gotō, Yoshiaki; Ohtani, Natsuki; Sugiyama, Kentaro; Tatezaki, Eriko; Sato, Mariko; Makino, Eiji; Shimada, Toru; Ueda, Chise; Matsuo, Ayumi; Suyama, Yoshihisa; Sakai, Yoshifumi; Furukawa, Masaru; Usami, Katsuki; Yoneyama, Hiroshi; Aso, Hisashi; Tanaka, Hidekazu; Nochi, Tomonori

doi:10.1186/s40168-021-01217-4

Cited by 22 publications

(16 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diarrhea is a high-risk disease in newborn calves, inducing gut microbiota dysbiosis, metabolic disorders, and even death ( 25 ). Therefore, enhancing the gut microbiota may contribute to preventing and alleviating diarrhea ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Pueraria lobata polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Shen

Shen²,

You³

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

IntroductionNeonatal calf diarrhea (NCD) is still one of the most critical diseases in calf rearing. Studies have shown that Pueraria lobata polysaccharides (PLP) have intense antioxidant and immunomodulatory activity and modulate gut microbiota. This randomized clinical trial aimed to determine the effect of PLP on the neonatal calf with diarrhea.MethodsIn this study, we recorded the fecal score of experimental calves, and calves with fecal scores ≥ 2 were determined as diarrhea and assessed their serum concentrations of inflammatory cytokines and oxidative damage-related indices. Fecal microbiota and metabolomics of diarrheal calves were further investigated.ResultsResults showed that treatment with PLP decreased the fecal score of diarrheal calves, serum concentrations of IL-1β, TNF-γ, and malondialdehyde, and also elevated the level of superoxide dismutase. In addition, PLP treatment altered the gut microbiota, significantly increased the relative abundances of beneficial bacteria, including the phyla Bacteroidetes and Actinobacteria, the genus Collinsella, Megamonas, and Bifidobacterium; decreased the relative abundances of pathogenetic or diarrhea related bacteria, such as Proteobacteria, Fusobacteria, Clostridium_sensu_stricto_1, and Escherichia_Shigella. Moreover, PLP can increase the fecal concentrations of isobutyric acid, propionic acid, and pantothenate; lower the levels of PC [18:0/18:1(9Z)], arachidonic acid, and docosahexaenoic acid.DiscussionThus, the results suggested that the PLP may perform the therapeutic activity via alleviating intestinal inflammation and regulating gut microbiota, avoiding further dysbiosis to restore the metabolism of gut microbiota, and finally promoting the recovery of diarrhea. The change further mitigated intestinal inflammation and oxidative damage in diarrheal calves. This indicated that PLP might be a promising treatment to attenuate diarrhea in neonatal calves.

show abstract

Section: Discussionmentioning

confidence: 99%

Pueraria lobata polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Shen

Shen²,

You³

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…Diarrhea is a high-risk disease in newborn calves, inducing gut microbiota dysbiosis, metabolic disorder, and even death [25]. Therefore, enhancing the gut microbiota may contribute to preventing and alleviating diarrhea [26].…”

Section: Discussionmentioning

confidence: 99%

Pueraria lobate polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Shen

Zhu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Neonatal calf diarrhea (NCD) is still one of the most critical diseases in calf rearing. Studies have shown that Pueraria lobata polysaccharides (PLP) have intense antioxidant and immunomodulatory activity and modulate gut microbiota. This randomized clinical trial aimed to investigate the effect of PLP on fecal score, inflammatory cytokines, antioxidant activity, fecal microbiota and metabolites in diarrheic calves. Methods 12 neonatal calves (7–8 day ages and 45–55 kg weights) with fecal scores ≥ 2 were determined as diarrhea then orally administered PLP (400mg/kg BW) QD for five consecutive days. 12 age-matched healthy calves with a fecal score ≤ 1 were selected as the control group. Fecal samples and blood samples were collected from the rectum and tail of diarrheic calves (DS) and calves in the control group (HS) on the 0 d; then collected fecal samples and blood samples from diarrheic calves treated with PLP (TS) on the 7 d of the trial. Fecal or blood samples of these calves were analyzed in inflammatory cytokines, antioxidant activity, fecal microbiota and metabolites. Results Studies showed that treatment with PLP decreased the fecal score of diarrheal calves, serum concentrations of IL-1β, TNF-α, and malondialdehyde, and also elevated the level of superoxide dismutase. In addition, PLP treatment altered the gut microbiota, significantly increased the relative abundances of beneficial bacteria, including the phyla Bacteroidetes and Actinobacteria, the genus Collinsella, Megamonas and Bifidobacterium; decreased the relative abundances of pathogenetic or diarrhea related bacteria, such as Proteobacteria, Fusobacteria, Clostridium_sensu_stricto_1, and Escherichia_Shigella. Moreover, PLP can increase the fecal concentrations of isobutyric acid, propionic acid, and pantothenate; lower the levels of PC (18:0/18:1(9Z)), arachidonic acid, and docosahexaenoic acid. Conclusions PLP perform the therapeutic activity via alleviating intestinal inflammation and regulating gut microbiota, avoiding further dysbiosis to restore the metabolism of gut microbiota, and finally promoting the recovery of diarrhea. The change further mitigated intestinal inflammation and oxidative damage in diarrheal calves.

show abstract

“…The fecal DNA extraction procedure and 16s rRNA gene amplicon (V3-V4 regions) sequencing were performed according to a previously published protocol (Islam et al, 2022). Additionally, demultiplexed raw sequences were obtained from the BaseSpace Sequence Hub (Illumina, San Diego, CA, USA), and the sequences were further analyzed using the QIIME 2 bioinformatics pipeline (version 2020.2) (Bolyen et al, 2019;Islam et al, 2022).…”

Section: Microbiota Analysismentioning

confidence: 99%

Effects of early-life tosufloxacin tosilate hydrate administration on growth rate, neurobehavior, and gut microbiota at adulthood in male mice

et al. 2023

Self Cite

View full text Add to dashboard Cite

Reportedly, antibiotics, which are frequently prescribed in children, have long-term effects owing to gut microbiota dysregulation. Tosufloxacin tosilate hydrate (TFLX) is the first orally administered new quinolone with high efficacy and broad-spectrum action approved as an antibacterial agent for pediatric use in Japan. However, studies on the effects of its early-stage administration are limited. Therefore, we aimed to analyze the later effects of its developmental administration by monitoring growth rate, neurobehavior, and gut microbiota in mice. The TFLX was administered via drinking water at a dose of up to 300 mg/kg for two consecutive weeks during the developmental period (4-6 weeks of age) or adulthood (8-10 weeks of age). Thereafter, the body weights of the mice were measured weekly to monitor growth rate. Behavioral tests were also conducted on 11-12-week-old mice to examine the neurobehavioral effects of the treatment. Further, to examine the effects of the treatment on microbiota, fecal samples were collected from the rectum of mice dissected at 12 weeks of age, and 16s rRNA analysis was conducted. Our results showed increased body weights after TFLX administration, without any long-term effects. Behavioral analysis suggested alterations in anxiety-like behaviors and memory recall dysregulation, and gut microbiota analysis revealed significant differences in bacterial composition. These findings indicated that TFLX administration during the developmental period affects mice growth rate, neurobehavior, and gut microbiota structure. This is the first study to report that TFLX is potentially associated with the risk of long effects.

show abstract

Development of a rational framework for the therapeutic efficacy of fecal microbiota transplantation for calf diarrhea treatment

Cited by 22 publications

References 59 publications

Pueraria lobata polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Pueraria lobata polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Pueraria lobate polysaccharides alleviate neonatal calf diarrhea by modulating gut microbiota and metabolites

Effects of early-life tosufloxacin tosilate hydrate administration on growth rate, neurobehavior, and gut microbiota at adulthood in male mice

Contact Info

Product

Resources

About